{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:37:51Z","timestamp":1786538271545,"version":"build-2736575974"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            This study evaluated the pulmonary disposition of eravacycline in 20 healthy adult volunteers receiving 1.0 mg of eravacycline\/kg intravenously every 12 h for a total of seven doses over 4 days. Plasma samples were collected at 0, 1, 2, 4, 6, and 12 h on day 4, with each subject randomized to undergo a single bronchoalveolar lavage (BAL) at 2, 4, 6, or 12 h. Drug concentrations in plasma, BAL fluid, and alveolar macrophages (AM) were determined by liquid chromatography-tandem mass spectrometry, and the urea correction method was used to calculate epithelial lining fluid (ELF) concentrations. Pharmacokinetic parameters were estimated by noncompartmental methods. Penetration for ELF and AM was calculated by using a ratio of the area under the concentration time curve (AUC\n            <jats:sub>0\u201312<\/jats:sub>\n            ) for each respective parameter against free drug AUC (\n            <jats:italic>f<\/jats:italic>\n            AUC\n            <jats:sub>0\u201312<\/jats:sub>\n            ) in plasma. The total AUC\n            <jats:sub>0\u201312<\/jats:sub>\n            in plasma was 4.56 \u00b1 0.94 \u03bcg\u00b7h\/ml with a mean\n            <jats:italic>f<\/jats:italic>\n            AUC\n            <jats:sub>0\u201312<\/jats:sub>\n            of 0.77 \u00b1 0.14 \u03bcg\u00b7h\/ml. The eravacycline concentrations in ELF and AM at 2, 4, 6, and 12 h were means \u00b1 the standard deviations (\u03bcg\/ml) of 0.70 \u00b1 0.30, 0.57 \u00b1 0.20, 0.34 \u00b1 0.16, and 0.25 \u00b1 0.13 with a penetration ratio of 6.44 and 8.25 \u00b1 4.55, 5.15 \u00b1 1.25, 1.77 \u00b1 0.64, and 1.42 \u00b1 1.45 with a penetration ratio of 51.63, respectively. The eravacycline concentrations in the ELF and AM achieved greater levels than plasma by 6- and 50-fold, respectively, supporting further study of eravacycline for patients with respiratory infections.\n          <\/jats:p>","DOI":"10.1128\/aac.02036-13","type":"journal-article","created":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T05:28:10Z","timestamp":1390886890000},"page":"2113-2118","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":108,"title":["Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women"],"prefix":"10.1128","volume":"58","author":[{"given":"Kevin P.","family":"Connors","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth T.","family":"Housman","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Samuel","family":"Pope","sequence":"additional","affiliation":[{"name":"CT Multispecialty Group, Pulmonary Division, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Russomanno","sequence":"additional","affiliation":[{"name":"CT Multispecialty Group, Pulmonary Division, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Salerno","sequence":"additional","affiliation":[{"name":"CT Multispecialty Group, Pulmonary Division, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Shore","sequence":"additional","affiliation":[{"name":"CT Multispecialty Group, Pulmonary Division, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Redican","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp256"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/524891"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir475"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01169-07"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/003335490712200205"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070099"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_3_2_11_2","volume-title":"Abstr","author":"Solomkin J","year":"2012","unstructured":"SolomkinJCesnauskaGRameshMWalpoleSSutcliffeJHornP. 2012. Efficacy and safety of TP-434 (eravacycline) versus ertapenem in complicated intra-abdominal infection (cIAI). Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr L1-1647a."},{"key":"e_1_3_2_12_2","volume-title":"Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-015","author":"Singh RSP","year":"2013","unstructured":"SinghRSPFalcaoNMSSutcliffeJDerendorfH. 2013. Plasma protein binding of eravacycline in mouse, rat, rabbit, cynomolgus monkey, African green monkey and human using microdialysis. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-015."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.3.965"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00133-06"},{"key":"e_1_3_2_15_2","volume-title":"Abstr 50th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Sutcliffe J","year":"2010","unstructured":"SutcliffeJRonnMLeightonASprengerC. 2010. Phase 1 single ascending dose study of a broad-spectrum fluorocycline, TP-434. Abstr 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr A1-027."},{"key":"e_1_3_2_16_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Yue CS","year":"2010","unstructured":"YueCSSutcliffeJAColucciPSprengerCRDucharmeMP. 2010. Population pharmacokinetic modeling of TP-434, a novel fluorocycline, following single and multiple dose administration. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr A1-028."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01042-09"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05354-11"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.02.013"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/431676"},{"key":"e_1_3_2_21_2","volume-title":"U.S. National Health and Nutrition Examination Survey, 1999-2002","author":"CDC","year":"2002","unstructured":"CDC. 2002. U.S. National Health and Nutrition Examination Survey, 1999-2002. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/nchs\/data\/ad\/ad347.pdf."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.6.1171"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.49.2.104"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00065-07"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1987.135.6.1276"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1986.60.2.532"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02036-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02036-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:40:41Z","timestamp":1645483241000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02036-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1128\/AAC.02036-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.02036-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"2013-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-01-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}